Attention around pharmacovigilance transformation potential has tended to focus on automating discrete steps in the ...
Oncology remains the leading M&A magnet, with ASCO data catalyzing interest in new combinations and next-generation ...
As Eli Lilly moves forward with its $3.5 billion injectable medicines facility in the Lehigh Valley region of Pennsylvania, ...
Eli Lilly was attracted by a deliberately cultivated life sciences strategy anchored in a region where manufacturing ...
At CPHI Americas 2026, PharmTech spoke with Dr. Molly Klote, president and CEO, Klote Medical Research Advisors, and ...
A Class II recall was initiated for duloxetine lots after N-nitroso-duloxetine exceeded FDA intake limits, reflecting low acute clinical risk but regulatory nonconformance. Nitrosamine issues ...
FDA’s durable expectation is that AI outputs can aid drafting, but must be reviewed and cleared by an authorized QU ...
The US Pharmacopeia’s 2025 annual drug shortages report found that while the total number of shortages declined by 23% in ...
Valuation compression in 1H26 largely stemmed from tighter underwriting standards, with buyers resisting inflated pricing and elevating diligence thresholds rather than stepping away from high-quality ...
USTR framed German payer discounts as an unfair R&D free‑ride and signaled tariffs could be avoided via negotiated price commitments, mirroring the recent UK NHS arrangement. Tariffs on US-bound ...
A comprehensive approach to long-term sustainability efforts in pharmaceutical manufacturing should prioritize simpler frameworks that curb costs, risks, and variability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results